Vessel Due F, 600 le/2ml 2 ml 10 pcs

Vessel® Due F (sulodexide) is a biological medicine which is a natural mixture of glycosaminoglycans (GAGs): a heparin-like fraction with a molecular weight of 8000 dalton (80%) and dermatansulfate (20%).

The mechanism of action of sulodexide is due to two main properties: the fast acting heparin-like fraction has an affinity for antithrombin III (ATIII) and the dermatan-like fraction has an affinity for heparin cofactor II (KGII).

Pharmacological action:

angioprotective, profibrinolytic, anticoagulant, antithrombotic.

Pharmacodynamics

The angioprotective effect is associated with restoration of structural and functional integrity of vascular endothelial cells, with restoration of the normal density of the negative electric charge of pores of the basal membrane of vessels. Besides, the preparation normalizes rheological properties of blood due to reduction of triglycerides level (it stimulates lipolytic enzyme – lipoprotein lipase which hydrolyzes triglycerides being a part of LDL).

The effectiveness of the drug in diabetic nephropathy is determined by the ability of sulodexide to decrease the thickness of basal membrane and extracellular matrix production due to decrease of mesangium cell proliferation.

Profibrinolytic effect is due to an increase in blood levels of tissue plasminogen activator and a decrease of its inhibitor.

The anticoagulant effect of the solution for intravenous and intramuscular administration, which is weakly expressed in the suggested dosage (one ampoule per day) is due to affinity for antithrombin and heparin cofactor II, which consistently reduces the concentrations of activated factor X and thrombin.

The antithrombotic activity is the result of all the actions that sulodexide has on the vascular wall (angioprotective effect), fibrinolysis (profibrinolytic effect), blood clotting (weak anticoagulant effect) and inhibition of platelet adhesion.

Pharmacokinetics

The absorption of sulodexide administered intravenously or intramuscularly is fairly rapid and depends on the rate of blood circulation at the injection site. Plasma concentrations of sulodexide after internal bolus administration of a single dose of 50 mg after 15, 30, and 60 minutes were 3.86 ± 0.37 mg/L, 1.87 ± 0.39 mg/L, and 0.98 ± 0.09 mg/L, respectively.

Sulodexide is distributed in the vascular endothelium at a concentration 20-30 times greater than that in other tissues. It is metabolized in the liver and excreted mainly by the kidneys. In a study of the radioactive labeled drug, 55.23% of sulodexide was excreted with the urine during the first 96 hours.

Indications

Active ingredient

Composition

How to take, the dosage

1 ampoule a day, intramuscularly or intravenously, for 15-20 days. Then the therapy should be continued for 30-40 days taking the drug orally in the form of capsules. Administration of 1-2 capsules 2 times a day before meals.

The full course of treatment should be repeated at least twice a year.

The dosing regimen can be changed at the discretion of the physician, depending on the results of the clinical and diagnostic examination of the patient.

Interaction

Special Instructions

At the beginning and end of treatment it is advisable to determine the following parameters: activated partial thromboplastin time, antithrombin III, bleeding time and clotting time. Vessel® Due F increases normal activated partial thromboplastin time by approximately one and a half times.

Influence on driving and operating ability

The ability to drive and operate vehicles and machines is not affected by Vessel® Due F.

Contraindications

Side effects

Overdose

Pregnancy use

In pregnancy Vessel Due F is prescribed under the close supervision of a physician.

There is positive experience of use for the treatment and prevention of vascular complications in patients with type 1 diabetes in the second and third trimesters of pregnancy, in the development of late toxicosis of pregnant women – gestosis.